## Aviv Shachak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2953395/publications.pdf Version: 2024-02-01

		26610	27389
215	13,957	56	106
papers	citations	h-index	g-index
223	223	223	15516
all docs	docs citations	times ranked	citing authors

Δυιν Shachak

#	Article	IF	CITATIONS
1	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. Journal of Affective Disorders, 2022, 296, 514-521.	2.0	10
2	Pharmacogenomics of ketamine: A systematic review. Journal of Psychiatric Research, 2022, 145, 27-34.	1.5	18
3	Olanzapine and samidorphan combination treatment: A systematic review. Journal of Affective Disorders, 2022, 301, 99-106.	2.0	11
4	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2022, 101, 93-135.	2.0	670
5	Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. Journal of Affective Disorders, 2022, 300, 172-178.	2.0	6
6	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 300, 449-461.	2.0	34
7	The effects of antidepressant medications on antiretroviral treatment adherence in HIV-positive individuals with depression. Journal of Affective Disorders, 2022, 300, 219-225.	2.0	3
8	Understanding Decision-Making in the Adoption of Digital Health Technology: The Role of Behavioral Economics' Prospect Theory. Journal of Medical Internet Research, 2022, 24, e32714.	2.1	7
9	Decision-making for Parents of Children With Medical Complexities: Activity Theory Analysis. Journal of Participatory Medicine, 2022, 14, e31699.	0.7	3
10	Immune response to vaccination in adults with mental disorders: A systematic review. Journal of Affective Disorders, 2022, 304, 66-77.	2.0	14
11	The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review. Journal of Psychiatric Research, 2022, 149, 252-259.	1.5	13
12	The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation. Journal of Affective Disorders, 2022, 304, 78-84.	2.0	6
13	Meta-analytic evidence of depression and anxiety in Eastern Europe during the COVID-19 pandemic. European Journal of Psychotraumatology, 2022, 13, 2000132.	0.9	45
14	The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. Psychiatry Research, 2022, 313, 114577.	1.7	2
15	Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. Psychiatry Research, 2022, 312, 114579.	1.7	5
16	Comprehensive review of the current literature on impact of ambient air pollution and sleep quality. Sleep Medicine, 2021, 79, 211-219.	0.8	31
17	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110032.	2.5	6
18	Characterizing the gut microbiota in adults with bipolar disorder: a pilot study. Nutritional Neuroscience, 2021, 24, 173-180.	1.5	34

#	Article	IF	CITATIONS
19	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Journal of Psychiatric Research, 2021, 134, 57-68.	1.5	58
20	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. Neuroscience and Biobehavioral Reviews, 2021, 120, 78-85.	2.9	48
21	The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 108, 110078.	2.5	7
22	Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opinion on Emerging Drugs, 2021, 26, 63-74.	1.0	27
23	<i>Social informatics</i> is a poor choice of term: A response to Pantell et al. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1356-1357.	2.2	3
24	Income-Generating Processes of Free Web-Based Digital Health Tools to Engage Patients: Qualitative Analysis. Journal of Medical Internet Research, 2021, 23, e23654.	2.1	4
25	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). Journal of Psychiatric Research, 2021, 135, 311-317.	1.5	15
26	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. Journal of Affective Disorders, 2021, 282, 448-453.	2.0	9
27	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. Psychiatry Research, 2021, 298, 113800.	1.7	7
28	Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 123, 203-214.	2.9	34
29	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. Journal of Psychiatric Research, 2021, 137, 426-436.	1.5	27
30	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry, 2021, 178, 383-399.	4.0	270
31	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. Journal of Psychiatric Research, 2021, 137, 232-241.	1.5	25
32	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. Journal of Affective Disorders, 2021, 286, 360-369.	2.0	36
33	The impact of overweight/obesity on monetary reward processing: A systematic review. Journal of Psychiatric Research, 2021, 137, 456-464.	1.5	9
34	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of Psychiatric Research, 2021, 139, 71-81.	1.5	47
35	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. Journal of Affective Disorders, 2021, 290, 364-377.	2.0	159
36	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). Psychiatry Research, 2021, 302, 113993.	1.7	16

#	Article	IF	CITATIONS
37	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. Journal of Affective Disorders, 2021, 292, 714-719.	2.0	5
38	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. American Journal of Geriatric Psychiatry, 2021, 29, 899-913.	0.6	24
39	Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. Journal of Psychiatric Research, 2021, 144, 129-137.	1.5	214
40	Surrogate Markers of Insulin Resistance in Predicting Major Depressive Disorder: Metabolism Metastasizes to the Brain. American Journal of Psychiatry, 2021, 178, 885-887.	4.0	8
41	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. Journal of Affective Disorders, 2021, 294, 592-596.	2.0	10
42	Added burden of major depressive disorder on cardiovascular morbidity and mortality among patients with cardiovascular disease and the modifying effects of antidepressants: A national retrospective cohort study. Journal of Affective Disorders, 2021, 294, 580-585.	2.0	3
43	Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 2021, 131, 192-210.	2.9	15
44	Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Research, 2021, 306, 114231.	1.7	11
45	The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality. Journal of Psychiatric Research, 2021, 144, 312-319.	1.5	9
46	Functional near-infrared spectroscopy during the verbal fluency task of English-Speaking adults with mood disorders: A preliminary study. Journal of Clinical Neuroscience, 2021, 94, 94-101.	0.8	14
47	Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg. American Journal of Psychiatry, 2021, 178, 1130-1132.	4.0	3
48	Are early increases in physical activity a behavioral marker for successful antidepressant treatment?. Journal of Affective Disorders, 2020, 260, 287-291.	2.0	4
49	The citation advantage of promoted articles in a crossâ€publisher distribution platform: A 12â€month randomized controlled trial. Journal of the Association for Information Science and Technology, 2020, 71, 1257-1274.	1.5	6
50	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. Psychiatry Research, 2020, 294, 113514.	1.7	156
51	C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders. Nutrients, 2020, 12, 3019.	1.7	5
52	Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. Journal of Affective Disorders, 2020, 277, 30-38.	2.0	27
53	Bipolar disorders. Lancet, The, 2020, 396, 1841-1856.	6.3	419
54	Impact of COVID-19 pandemic on mental health in the general population: A systematic review. Journal of Affective Disorders, 2020, 277, 55-64.	2.0	3,399

#	Article	IF	CITATIONS
55	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. Journal of Affective Disorders, 2020, 276, 576-584.	2.0	118
56	Effective Design, Development, and Evaluation of Video Tutorials for Electronic Medical Record Training. ACI Open, 2020, 04, e69-e82.	0.2	0
57	In vivo phenotyping, mechanismâ€informed treatments, domainâ€based psychopathology and nomological networks: A strategy for treatment discovery and development in bipolar depression. Bipolar Disorders, 2020, 22, 657-659.	1.1	10
58	Virtual care: a â€~Zoombie' apocalypse?. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1813-1815.	2.2	16
59	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disorders, 2020, 22, 440-460.	1.1	66
60	The utility of smartphone-based, ecological momentary assessment for depressive symptoms. Journal of Affective Disorders, 2020, 274, 602-609.	2.0	40
61	What makes difficult decisions so difficult?: An activity theory analysis of decision making for physicians treating children with medical complexity. Patient Education and Counseling, 2020, 103, 2260-2268.	1.0	4
62	PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder. Journal of Affective Disorders, 2020, 273, 586-591.	2.0	11
63	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. Journal of Psychiatric Research, 2020, 124, 137-142.	1.5	1
64	Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update—Reader Comment. Journal of Cutaneous Medicine and Surgery, 2020, 24, 213-215.	0.6	0
65	156 The Broad Efficacy of Cariprazine Across Symptoms in Patients with Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials. CNS Spectrums, 2020, 25, 300-300.	0.7	0
66	Current and Future Vistas in Bipolar Disorder. Current Behavioral Neuroscience Reports, 2020, 7, 68-75.	0.6	0
67	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. Journal of Affective Disorders, 2020, 272, 1-7.	2.0	28
68	Registered clinical trials investigating ketamine for psychiatric disorders. Journal of Psychiatric Research, 2020, 127, 1-12.	1.5	22
69	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain, Behavior, and Immunity, 2020, 88, 631-639.	2.0	44
70	Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder. Psychiatry Research, 2020, 284, 112767.	1.7	2
71	Projected increases in suicide in Canada as a consequence of COVID-19. Psychiatry Research, 2020, 290, 113104.	1.7	149
72	Mental health conditions among the general population, healthcare workers and quarantined population during the coronavirus disease 2019 (COVID-19) pandemic. Psychology, Health and Medicine, 2020, , 1-13.	1.3	19

#	Article	IF	CITATIONS
73	Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 2019, 9, 190.	2.4	231
74	Beyond TAM and UTAUT: Future directions for HIT implementation research. Journal of Biomedical Informatics, 2019, 100, 103315.	2.5	100
75	Machine learning and big data: Implications for disease modeling and therapeutic discovery in psychiatry. Artificial Intelligence in Medicine, 2019, 99, 101704.	3.8	100
76	Evaluating a post-implementation electronic medical record training intervention for diabetes management in primary care. BMJ Health and Care Informatics, 2019, 26, e100086.	1.4	8
77	Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. Experimental Neurology, 2019, 315, 1-8.	2.0	82
78	Stress, epigenetics and depression: A systematic review. Neuroscience and Biobehavioral Reviews, 2019, 102, 139-152.	2.9	246
79	Consumer Warning for Genetic Tests Claiming to Predict Response to Medications: Implications for Psychiatry. American Journal of Psychiatry, 2019, 176, 412-413.	4.0	1
80	67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder. CNS Spectrums, 2019, 24, 210-211.	0.7	0
81	28 How is Postpartum Depression Currently Diagnosed and Managed? Insights from a Virtual Patient Simulation. CNS Spectrums, 2019, 24, 189-190.	0.7	1
82	Educational approaches for improving physicians' use of health information technology. Healthcare Management Forum, 2019, 32, 188-191.	0.6	6
83	The neural systems of emotion regulation and abnormalities in major depressive disorder. Behavioural Brain Research, 2019, 367, 181-188.	1.2	70
84	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 387-404.	2.5	51
85	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 1-7.	2.5	30
86	The long-term effect of bariatric surgery on depression and anxiety. Journal of Affective Disorders, 2019, 246, 886-894.	2.0	117
87	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums, 2019, 24, 154-162.	0.7	18
88	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 109-117.	2.5	93
89	Risk of Dementia Among Individuals With Psoriasis. Journal of Clinical Psychiatry, 2019, 80, .	1.1	22
90	Differential Diagnosis of Major Depressive Disorder Versus Bipolar Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	9

#	Article	IF	CITATIONS
91	Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning. Journal of Clinical Psychiatry, 2019, 80, .	1.1	2
92	Tools for Engaging Patients on Patient Platforms: A Classification Framework. Studies in Health Technology and Informatics, 2019, 257, 256-260.	0.2	2
93	The relationship of depression with the level of blood pressure in population-based Kangbuk Samsung Health Study. Journal of the American Society of Hypertension, 2018, 12, 356-363.	2.3	5
94	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 189-204.	2.5	37
95	Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. International Journal of Neuropsychopharmacology, 2018, 21, 128-144.	1.0	68
96	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. Journal of Affective Disorders, 2018, 227, 219-225.	2.0	135
97	Cognitive Impairment Mediates Workplace Impairment in Adults With Type 2 Diabetes Mellitus: Results From the Motivaction Study. Canadian Journal of Diabetes, 2018, 42, 289-295.	0.4	19
98	Sex differences in the mediators of functional disability in Major Depressive Disorder. Journal of Psychiatric Research, 2018, 96, 108-114.	1.5	14
99	Food addiction: Prevalence, psychopathological correlates and associations with quality of life in a large sample. Journal of Psychiatric Research, 2018, 96, 145-152.	1.5	115
100	Correlation between brain circuit segregation and obesity. Behavioural Brain Research, 2018, 337, 218-227.	1.2	34
101	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. Journal of Affective Disorders, 2018, 227, 406-415.	2.0	91
102	Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. Research in Developmental Disabilities, 2018, 72, 96-105.	1.2	44
103	Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Therapeutic Advances in Psychopharmacology, 2018, 8, 337-348.	1.2	50
104	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. Journal of Psychiatric Research, 2018, 107, 136-137.	1.5	1
105	Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sciences, 2018, 210, 177-184.	2.0	61
106	Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder. Harvard Review of Psychiatry, 2018, 26, 241-249.	0.9	17
107	The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats. Pharmacological Reports, 2018, 70, 1173-1179.	1.5	2
108	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 95-101.	2.5	34

#	Article	IF	CITATIONS
109	Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Research Bulletin, 2018, 142, 1-7.	1.4	70
110	Predicting antidepressant response using early changes in cognition: A systematic review. Behavioural Brain Research, 2018, 353, 154-160.	1.2	28
111	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. Brain, Behavior, and Immunity, 2018, 73, 115-124.	2.0	90
112	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. Journal of Affective Disorders, 2018, 241, 519-532.	2.0	179
113	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. Journal of Affective Disorders, 2018, 241, 484-491.	2.0	94
114	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. Journal of Affective Disorders, 2018, 238, 228-232.	2.0	11
115	Leptin and adiponectin levels in major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2018, 238, 101-110.	2.0	59
116	Gaming-addicted teens identify more with their cyber-self than their own self: Neural evidence. Psychiatry Research - Neuroimaging, 2018, 279, 51-59.	0.9	20
117	Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder. Journal of Clinical Psychiatry, 2018, 79, .	1.1	29
118	Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia. Human Psychopharmacology, 2017, 32, e2585.	0.7	1
119	Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacological Research, 2017, 121, 213-218.	3.1	102
120	The Efficacy of Psychostimulants in Major Depressive Episodes. Journal of Clinical Psychopharmacology, 2017, 37, 412-418.	0.7	56
121	Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents. Human Psychopharmacology, 2017, 32, e2589.	0.7	13
122	Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectrums, 2017, 22, 333-341.	0.7	24
123	Reply to Comments by Drs Glue and Menkes. Journal of Clinical Psychopharmacology, 2017, 37, 384-385.	0.7	0
124	Pharmacological Approaches to Minimizing Cardiometabolic Side Effects of Mood Stabilizing Medications. Current Treatment Options in Psychiatry, 2017, 4, 319-332.	0.7	7
125	Factors affecting lumbar surgery outcome: A nation-wide, population-based retrospective study. Journal of Affective Disorders, 2017, 222, 98-102.	2.0	4
126	Online distribution channel increases article usage on Mendeley: a randomized controlled trial. Scientometrics, 2017, 112, 1537-1556.	1.6	16

#	Article	IF	CITATIONS
127	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	0.8	119
128	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. Journal of Affective Disorders, 2017, 222, 14-20.	2.0	39
129	The association between insulin resistance and depression in the Korean general population. Journal of Affective Disorders, 2017, 208, 553-559.	2.0	44
130	Evaluating Educational Interventions for Health Professions in the Digital Age. , 2017, , 471-488.		4
131	Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. Current Pharmaceutical Design, 2017, 23, 2065-2072.	0.9	27
132	Mobile Apps for Eye Care in Canada: An Analysis of the iTunes Store. JMIR MHealth and UHealth, 2017, 5, e84.	1.8	16
133	Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders. Dialogues in Clinical Neuroscience, 2017, 19, 27-36.	1.8	12
134	Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2017, 78, 115-121.	1.1	73
135	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. Journal of Clinical Psychiatry, 2017, 78, 873-881.	1.1	100
136	Functional Recovery in Major Depressive Disorder. primary care companion for CNS disorders, The, 2016, 18, .	0.2	51
137	Editorial (Thematic Issue: Mood Disorders and General Medical Comorbidities: Shared Biology and) Tj ETQq1 1 0	.784314 r 0.6	∙gBT <sub>a</sub> /Overlo⊂
138	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. Current Opinion in Pharmacology, 2016, 29, 63-69.	1.7	21
139	TrendMD: Helping scholarly content providers reach larger and more targeted audiences. Learned Publishing, 2016, 29, 125-129.	0.8	5
140	Cognition in major depressive disorder. Current Opinion in Psychiatry, 2016, 29, 48-55.	3.1	67
141	The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectrums, 2016, 21, 385-392.	0.7	9
142	Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions. Focus (American Psychiatric Publishing), 2016, 14, 184-193.	0.4	3
143	Sleep and Inflammation: Implications for Domain Approach and Treatment Opportunities. Biological Psychiatry, 2016, 80, 9-11.	0.7	7
144	Antiâ€inflammatory agents in the treatment of bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2016, 18, 89-101.	1.1	153

#	Article	IF	CITATIONS
145	Computers in the clinical encounter: a scoping review and thematic analysis. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 654-665.	2.2	95
146	Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. Obesity Research and Clinical Practice, 2016, 10, 531-543.	0.8	20
147	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. Neuroscience and Biobehavioral Reviews, 2016, 64, 148-166.	2.9	97
148	The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. International Journal of Neuropsychopharmacology, 2016, 19, pyv082.	1.0	174
149	Factors Differentiating Childhood-Onset and Adolescent-Onset Schizophrenia. primary care companion for CNS disorders, The, 2016, 18, .	0.2	10
150	Towards Educational Electronic Health Records (EHRs): A Design Process for Integrating EHRs, Simulation, and Video Tutorials. Studies in Health Technology and Informatics, 2016, 228, 624-8.	0.2	2
151	Depression and Employment Status in Primary and Tertiary Care Settings. Canadian Journal of Psychiatry, 2015, 60, 14-22.	0.9	59
152	The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Current Neuropharmacology, 2015, 13, 558-576.	1.4	110
153	Autobiographical Memory Disturbances in Depression: A Novel Therapeutic Target?. Neural Plasticity, 2015, 2015, 1-14.	1.0	65
154	Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. Psychoneuroendocrinology, 2015, 62, 18-26.	1.3	70
155	Causes of decreased life expectancy over the life span in bipolar disorder. Journal of Affective Disorders, 2015, 180, 142-147.	2.0	139
156	The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project. Comprehensive Psychiatry, 2015, 56, 279-282.	1.5	123
157	Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. Journal of Affective Disorders, 2015, 172, 337-346.	2.0	75
158	The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier―in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. Journal of Affective Disorders, 2015, 172, 259-264.	2.0	96
159	Weight cycling in bipolar disorder. Journal of Affective Disorders, 2015, 171, 33-38.	2.0	32
160	Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1804-1818.	0.8	151
161	Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features. Journal of Clinical Psychiatry, 2015, 76, 398-405.	1.1	57
162	A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. primary care companion for CNS disorders, The, 2015, 17, .	0.2	11

#	Article	IF	CITATIONS
163	An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder. primary care companion for CNS disorders, The, 2015, 17, .	0.2	0
164	Evidence-Based Treatment of Bipolar Disorder, Bipolar Depression, and Mixed Features. Journal of Family Practice, 2015, 64, S16-23.	0.2	0
165	A Pilot Study of Computer-Based Simulation Training for Enhancing Family Medicine Residents' Competence in Computerized Settings. Studies in Health Technology and Informatics, 2015, 216, 506-10.	0.2	14
166	Major depressive disorder and cognitive impairment. Journal of Psychiatry and Neuroscience, 2014, 39, E36-E37.	1.4	5
167	Advancing biomarker research: utilizing â€~Big Data' approaches for the characterization and prevention of bipolar disorder. Bipolar Disorders, 2014, 16, 531-547.	1.1	57
168	Screening for bipolar depression in family medicine practices: Prevalence and clinical correlates. Journal of Affective Disorders, 2014, 162, 120-127.	2.0	7
169	Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 2014, 156, 1-7.	2.0	337
170	Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia. Neuropharmacology, 2014, 77, 481-486.	2.0	12
171	Predicting and preventing bipolar disorder: the need to fundamentally advance the strategic approach. Bipolar Disorders, 2014, 16, 451-454.	1.1	7
172	Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. Journal of Psychiatric Research, 2014, 59, 28-37.	1.5	98
173	The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial. Psychiatry Research, 2014, 220, 245-250.	1.7	45
174	Treatment-Resistant Depression in Primary Care across Canada. Canadian Journal of Psychiatry, 2014, 59, 349-357.	0.9	120
175	Human factors in computing systems: Focus on patient-centered health communication at the ACM SIGCHI conference. Patient Education and Counseling, 2013, 93, 532-534.	1.0	14
176	Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. Journal of Affective Disorders, 2013, 151, 573-581.	2.0	48
177	User Manuals for a Primary Care Electronic Medical Record System: A Mixed-Methods Study of User- and Vendor-Generated Documents. IEEE Transactions on Professional Communication, 2013, 56, 194-209.	0.6	8
178	The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Human Psychopharmacology, 2013, 28, 421-427.	0.7	22
179	Patient-Physician Interactions and Electronic Health Records. JAMA - Journal of the American Medical Association, 2013, 310, 1857.	3.8	6
180	End-user support for primary care electronic medical records: a qualitative case study of users' needs, expectations, and realities. Health Systems, 2013, 2, 198-212.	0.9	14

#	Article	IF	CITATIONS
181	Developing a Tool to Assess the Quality of Socio-Demographic Data in Community Health Centres. Applied Clinical Informatics, 2013, 04, 1-11.	0.8	6
182	End-user support for a primary care electronic medical record: a qualitative case study of a vendor's perspective. Informatics in Primary Care, 2013, 20, 185.	1.1	10
183	What Do Electronic Health Record Vendors Reveal About Their Products: An Analysis of Vendor Websites. Journal of Medical Internet Research, 2013, 15, e36.	2.1	4
184	The use of tags and tag clouds to discern credible content in online health message forums. International Journal of Medical Informatics, 2012, 81, 36-44.	1.6	24
185	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Annals of Clinical Psychiatry, 2012, 24, 2-3.	0.6	39
186	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Annals of Clinical Psychiatry, 2012, 24, 69-81.	0.6	70
187	Is Qualitative Research Second Class Science? A Quantitative Longitudinal Examination of Qualitative Research in Medical Journals. PLoS ONE, 2011, 6, e16937.	1.1	66
188	Understanding end-user support for health information technology: a theoretical framework. Journal of Innovation in Health Informatics, 2011, 19, 169-172.	0.9	11
189	A 52-Week, Double-Blind Evaluation of the Metabolic Effects of Aripiprazole and Lithium in Bipolar I Disorder. primary care companion for CNS disorders, The, 2011, 13, .	0.2	11
190	Electronic Health Records in the Age of Social Networks and Global Telecommunications. JAMA - Journal of the American Medical Association, 2010, 303, 452.	3.8	33
191	The Computer-Assisted Patient Consultation. Advances in Healthcare Information Systems and Administration Book Series, 2010, , 72-83.	0.2	2
192	Using multi-perspective methodologies to study users' interactions with the prototype front end of a guideline-based decision support system for diabetic foot care. International Journal of Medical Informatics, 2009, 78, 482-493.	1.6	40
193	Primary Care Physicians' Use of an Electronic Medical Record System: A Cognitive Task Analysis. Journal of General Internal Medicine, 2009, 24, 341-348.	1.3	150
194	The impact of electronic medical records on patient–doctor communication during consultation: a narrative literature review. Journal of Evaluation in Clinical Practice, 2009, 15, 641-649.	0.9	226
195	A 3â€week, randomized, placeboâ€controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders, 2009, 11, 673-686.	1.1	176
196	Asenapine versus olanzapine in acute mania: a doubleâ€blind extension study. Bipolar Disorders, 2009, 11, 815-826.	1.1	105
197	Managing Weight Gain in Patients With Severe Mental Illness. Journal of Clinical Psychiatry, 2009, 70, e23.	1.1	12
198	Overview of Managing Medical Comorbidities in Patients With Severe Mental Illness. Journal of Clinical Psychiatry, 2009, 70, e17.	1.1	19

#	Article	IF	CITATIONS
199	Bipolar disorder and suicide: Research synthesis and clinical translation. Current Psychiatry Reports, 2008, 10, 66-72.	2.1	75
200	The Effect of training on biologists acceptance of bioinformatics tools: A field experiment. Journal of the Association for Information Science and Technology, 2008, 59, 719-730.	2.6	8
201	The Relationship Between Childhood Abuse and Suicidality in Adult Bipolar Disorder. Violence and Victims, 2008, 23, 361-372.	0.4	51
202	Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents. JAMA Pediatrics, 2008, 162, 929.	3.6	158
203	Recently patented agents with possible antipsychotic indication. Expert Opinion on Therapeutic Patents, 2008, 18, 1327-1332.	2.4	0
204	Structured versus unstructured tagging: a case study. Online Information Review, 2008, 32, 635-647.	2.2	37
205	Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues in Clinical Neuroscience, 2008, 10, 203-213.	1.8	28
206	Maintenance treatment in bipolar disorder: a focus on aripiprazole. Expert Review of Neurotherapeutics, 2007, 7, 919-925.	1.4	10
207	Barriers and enablers to the acceptance of bioinformatics tools: a qualitative study. Journal of the Medical Library Association: JMLA, 2007, 95, 454-458.	0.6	21
208	Evaluating primary care doctors' evidenceâ€based medicine skills in a busy clinical setting. Journal of Evaluation in Clinical Practice, 2007, 13, 576-580.	0.9	28
209	The Impact of an Evidence-Based Medicine Educational Intervention on Primary Care Physicians: A Qualitative Study. Journal of General Internal Medicine, 2007, 22, 327-331.	1.3	38
210	Obesity in Bipolar Disorder and Major Depressive Disorder: Results from a National Community Health Survey on Mental Health and Well-Being. Canadian Journal of Psychiatry, 2006, 51, 274-280.	0.9	133
211	Anxiety disorders and bipolar disorder: a review. Bipolar Disorders, 2006, 8, 665-676.	1.1	78
212	Diffusion pattern of the use of genomic databases and analysis of biological sequences from 1970–2003: Bibliographic record analysis of 12 journals. Journal of the Association for Information Science and Technology, 2006, 57, 44-50.	2.6	4
213	Applying Instructional Design Theories to Bioinformatics Education in Microarray Analysis and Primer Design Workshops. CBE: Life Sciences Education, 2005, 4, 199-206.	0.7	16
214	Immunological cross-reaction between bud and bark proteins of dormant deciduous trees. Scientia Horticulturae, 1998, 73, 165-173.	1.7	7
215	Rapid-acting antidepressants in psychiatry: episodic treatments, innovation, and clarion call for methodologic rigor in drug development. Expert Opinion on Drug Safety, 0, , 1-2.	1.0	3